Prothrombin Complex Concentrates are Superior to Fresh Frozen Plasma for Emergency Reversal of Vitamin K Antagonists: A Meta-Analysis in 2606 Subjects.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
12
8
2019
medline:
6
2
2020
entrez:
12
8
2019
Statut:
ppublish
Résumé
Urgent reversal of vitamin K antagonists (VKAs) is required for major bleeding or urgent surgery by intravenous vitamin K with either prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP). However, there is lack of consensus regarding the superiority of either reversal agent. We sought to compare the performance of PCC and FFP in urgent reversal of VKA. A meta-analysis was conducted up to November 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random effects model. Seventeen studies comprising 2606 participants met the inclusion criteria. Compared with FFP treatment, PCC treatment led to a reduction in 90-day all-cause mortality (OR 0.60, 95% CI 0.40-0.90, p = 0.01), better reversal of INR (OR 7.36, 95% CI 4.18-12.98; p < 0.00001) and lower risk of at least one treatment-related adverse event (OR 0.45, 95% CI 0.26-0.80, p = 0.006). Among patients with VKA-associated intracranial haemorrhage, PCC treatment led to a reduction in 90-day all-cause mortality (OR 0.58, 95% CI 0.35-0.94, p = 0.03) and better reversal of INR (OR 6.52, 95% CI 1.66-25.59, p = 0.007). There were no differences between these two agents in thrombogenicity, requirement for and quantity of red blood cell transfusions, all adverse events, fluid overload or disability on discharge or at 90 days. As an agent for urgent reversal of VKA, PCC outperforms FFP in 90-day all-cause mortality including those with VKA-related intracranial haemorrhage, INR reversal and treatment-related adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Urgent reversal of vitamin K antagonists (VKAs) is required for major bleeding or urgent surgery by intravenous vitamin K with either prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP). However, there is lack of consensus regarding the superiority of either reversal agent. We sought to compare the performance of PCC and FFP in urgent reversal of VKA.
METHODS
METHODS
A meta-analysis was conducted up to November 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random effects model.
RESULTS
RESULTS
Seventeen studies comprising 2606 participants met the inclusion criteria. Compared with FFP treatment, PCC treatment led to a reduction in 90-day all-cause mortality (OR 0.60, 95% CI 0.40-0.90, p = 0.01), better reversal of INR (OR 7.36, 95% CI 4.18-12.98; p < 0.00001) and lower risk of at least one treatment-related adverse event (OR 0.45, 95% CI 0.26-0.80, p = 0.006). Among patients with VKA-associated intracranial haemorrhage, PCC treatment led to a reduction in 90-day all-cause mortality (OR 0.58, 95% CI 0.35-0.94, p = 0.03) and better reversal of INR (OR 6.52, 95% CI 1.66-25.59, p = 0.007). There were no differences between these two agents in thrombogenicity, requirement for and quantity of red blood cell transfusions, all adverse events, fluid overload or disability on discharge or at 90 days.
CONCLUSIONS
CONCLUSIONS
As an agent for urgent reversal of VKA, PCC outperforms FFP in 90-day all-cause mortality including those with VKA-related intracranial haemorrhage, INR reversal and treatment-related adverse events.
Identifiants
pubmed: 31401731
doi: 10.1007/s40265-019-01179-w
pii: 10.1007/s40265-019-01179-w
doi:
Substances chimiques
Anticoagulants
0
Blood Coagulation Factors
0
Vitamin K
12001-79-5
prothrombin complex concentrates
37224-63-8
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1557-1565Références
Neurosurgery. 1999 Nov;45(5):1113-8; discussion 1118-9
pubmed: 10549927
Br J Neurosurg. 2000 Oct;14(5):458-61
pubmed: 11198768
Br J Haematol. 2001 Oct;115(1):145-9
pubmed: 11722425
Spine (Phila Pa 1976). 2003 Jun 15;28(12):1290-9
pubmed: 12811274
Br J Haematol. 2004 Jul;126(1):11-28
pubmed: 15198728
Neurology. 2004 Sep 28;63(6):1059-64
pubmed: 15452298
Stroke. 1992 Jul;23(7):972-7
pubmed: 1615547
Stroke. 2006 Jan;37(1):151-5
pubmed: 16306465
Stroke. 2006 Jun;37(6):1465-70
pubmed: 16675739
Arch Intern Med. 2007 Jul 9;167(13):1414-9
pubmed: 17620536
Am J Hematol. 2008 Feb;83(2):137-43
pubmed: 17729241
Lancet Neurol. 2008 May;7(5):391-9
pubmed: 18396107
Chest. 2008 Jun;133(6 Suppl):160S-198S
pubmed: 18574265
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Blood Transfus. 2010 Jul;8(3):149-54
pubmed: 20671873
Vox Sang. 2010 Oct;99(3):251-60
pubmed: 20840339
Br J Haematol. 2011 Aug;154(3):311-24
pubmed: 21671894
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Chest. 2012 Feb;141(2 Suppl):e152S-e184S
pubmed: 22315259
Circulation. 2013 Jul 23;128(4):360-4
pubmed: 23770745
Circulation. 2013 Sep 10;128(11):1234-43
pubmed: 23935011
Thromb Haemost. 2014 Feb;111(2):233-9
pubmed: 24154891
Am J Emerg Med. 2014 Jun;32(6):660-4
pubmed: 24661780
Neurocrit Care. 2014 Dec;21(3):397-406
pubmed: 24671832
Blood. 2014 Aug 7;124(6):955-62
pubmed: 24859362
Lancet. 2015 May 23;385(9982):2077-87
pubmed: 25728933
Ann Neurol. 2015 Jul;78(1):54-62
pubmed: 25857223
Cochrane Database Syst Rev. 2015 Jul 07;(7):CD010555
pubmed: 26151108
Iran J Pharm Res. 2015 Summer;14(3):877-85
pubmed: 26330876
J Emerg Med. 2016 Jan;50(1):1-6
pubmed: 26409668
Lancet Neurol. 2016 May;15(6):566-73
pubmed: 27302126
Thromb Haemost. 2016 Oct 28;116(5):879-890
pubmed: 27488143
Pharmacotherapy. 2016 Nov;36(11):1132-1137
pubmed: 27726162
Neurosurgery. 2018 Jun 1;82(6):877-886
pubmed: 29106685
Ann Thorac Surg. 2018 Apr;105(4):1152-1157
pubmed: 29397934
J Surg Res. 2018 Mar;223:183-187
pubmed: 29433872